Legend Biotech Corp (LEGN)

Currency in USD
28.51
+2.01(+7.58%)
Closed·
28.44-0.07(-0.25%)
·
Unusual trading volume
Earnings results expected in 0 days
LEGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
26.4430.41
52 wk Range
16.2445.30
Key Statistics
Prev. Close
26.5
Open
26.52
Day's Range
26.44-30.41
52 wk Range
16.24-45.3
Volume
6.58M
Average Volume (3m)
2.07M
1-Year Change
-14.6407%
Book Value / Share
5.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LEGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
57.24
Upside
+100.75%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Legend Biotech Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

14 Buy
2 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 57.24
(+100.75% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy50.00+75.38%-MaintainApr 21, 2026
Raymond James
Buy86.00+201.65%-MaintainApr 21, 2026
RBC Capital
Buy62.00+117.47%-MaintainApr 20, 2026
H.C. Wainwright
Buy50.00+75.38%-MaintainApr 20, 2026
H.C. Wainwright
Buy50.00+75.38%-MaintainApr 15, 2026

Legend Biotech Corp SWOT Analysis


Carvykti's Triumph
Legend Biotech's flagship product Carvykti drives remarkable 74.75% revenue growth, establishing itself as a leading treatment for multiple myeloma
Financial Fortitude
Explore Legend Biotech's robust liquidity position, with a current ratio of 4.71 and more cash than debt, despite negative EPS
Pipeline Potential
Delve into Legend Biotech's diverse pipeline, including promising CAR-T therapies for gastric, esophageal, and lung cancers, offering growth beyond Carvykti
Market Outlook
Analyst price targets range from $71 to $94, with an average of $82.20, reflecting confidence in Legend Biotech's growth prospects and pipeline potential
Read full SWOT analysis

Legend Biotech Corp Earnings Call Summary for Q4/2025

  • Legend Biotech reported Q4 2025 revenue of $306M, up 64% YoY, with EPS of $0.01 meeting forecasts despite slight revenue miss of $310.71M.
  • CARVYKTI franchise achieved profitability with $555M net trade sales annually; gross margin reached 61% with company-specific margin at 57%.
  • Operating margin improved dramatically from -142% in Q2 2023 to -6% in Q4 2025, targeting enterprise-wide profitability by 2026.
  • Stock rose 0.78% in premarket to $19.29; analysts maintain strong buy rating with price targets ranging from $21 to $86.
  • CEO Huang emphasized CARVYKTI's strength and global expansion plans; risks include CAR-T competition, supply chain issues, and regulatory changes.
Last Updated: 2026-03-10, 09:16 a/m
Read Full Transcript

Earnings

Latest Release
Mar 10, 2026
EPS / Forecast
0.01 / 0.01
Revenue / Forecast
306.3M / 310.71M
EPS Revisions
Last 90 days

LEGN Income Statement

Compare LEGN to Peers and Sector

Metrics to compare
LEGN
Peers
Sector
Relationship
P/E Ratio
−16.5x−2.6x−0.5x
PEG Ratio
0.26−0.090.00
Price/Book
4.9x3.9x2.6x
Price / LTM Sales
4.8x16.8x3.3x
Upside (Analyst Target)
114.9%381.4%47.1%
Fair Value Upside
Unlock9.8%6.2%Unlock

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
42.21M22.82%1.12B
Other Institutional Investors
149.11M77.18%3.95B
Public Companies & Retail Investors
0.000.00%0.00
Total
191.32M100.00%5.07B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Genscript Biotech Corporation47.18%87,248,7782,312,093
FMR LLC13.10%24,225,616641,979

People Also Watch

3.120
ESPR
0.00%
1.720
ALDX
+6.17%
3.47
BATL
-5.45%
2.170
ALLO
-3.98%

FAQ

What Is the Legend Bio (LEGN) Stock Price Today?

The Legend Bio stock price today is 28.51 USD.

What Stock Exchange Does Legend Bio Trade On?

Legend Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Legend Bio?

The stock symbol for Legend Bio is "LEGN."

What Is the Legend Bio Market Cap?

As of today, Legend Bio market cap is 5.29B USD.

What Is Legend Bio's Earnings Per Share (TTM)?

The Legend Bio EPS (TTM) is -1.62.

When Is the Next Legend Bio Earnings Date?

Legend Bio will release its next earnings report on May 19, 2026.

From a Technical Analysis Perspective, Is LEGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Legend Bio Stock Split?

Legend Bio has split 0 times.

How Many Employees Does Legend Bio Have?

Legend Bio has 2900 employees.

What is the current trading status of Legend Bio (LEGN)?

As of May 05, 2026, Legend Bio (LEGN) is trading at a price of 28.51 USD, with a previous close of 26.50 USD. The stock has fluctuated within a day range of 26.44 USD to 30.41 USD, while its 52-week range spans from 16.24 USD to 45.30 USD.

What Is Legend Bio (LEGN) Price Target According to Analysts?

The average 12-month price target for Legend Bio is 57.24 USD, with a high estimate of 86 USD and a low estimate of 21 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +100.75% Upside potential.

What Is the LEGN Premarket Price?

LEGN's last pre-market stock price is 26.45 USD. The pre-market share volume is 6,370.00, and the stock has decreased by -0.05, or -0.19%.

What Is the LEGN After Hours Price?

LEGN's last after hours stock price is 28.44 USD, the stock has decreased by -0.07, or -0.25%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.